Welcome to the ME 270 course website for the Fall 2025 term. The material on this site is a complement to the lecture book for the course. And, all material here is accessible without the need to log ...

The FDA approved imlunestrant for treatment of certain adults with breast cancer who experience disease progression after at least one prior line of endocrine therapy.